The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
812
February 23, 1990
View Complete Issue         Table of Contents 2019 
Anistreplase for Acute Coronary Thrombosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Anistreplase for Acute Coronary Thrombosis
February 23, 1990 (Issue: 812)
Anistreplase (Eminase - SmithKline Beecham, Upjohn), a plasminogen activator also known as APSAC, was recently approved by the US Food and Drug Administration (FDA) for intravenous (IV) thrombolytic treatment of coronary thrombosis. Three other...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Anistreplase for Acute Coronary Thrombosis
Article code: 812a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.